Cabometyx (cabozantinib) — United Healthcare

Initial criteria

• Diagnosis of differentiated thyroid cancer (DTC)
• Disease is locally advanced or metastatic
• Disease has progressed following prior VEGFR-targeted therapy
• Disease is radioactive iodine-refractory or ineligible

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Cabometyx therapy

Approval duration

12 months